Pamidronate treatment of pediatric fracture patients on chronic steroid therapy

Pediatric Nephrology

Volumn 20, Issue 3 SPEC. ISS., 2005, Pages 368-373

  Acott, Philip D ^a,b   Wong, Jaime A ^a   Lang, Bianca A ^a   Crocker, John F S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; Fractures; Pamidronate; Pediatrics; Steroids

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CREATININE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; STEROID;

ALLERGIC REACTION; ANALYSIS OF VARIANCE; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM EXCRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FLU LIKE SYNDROME; FRACTURE; HUMAN; HYPOCALCEMIA; MALE; OSTEOPENIA; PHLEBITIS; PHOSPHATE EXCRETION; PRIORITY JOURNAL; RIB FRACTURE; RISK ASSESSMENT; SPINE FRACTURE; STEROID THERAPY; THROMBOPHLEBITIS; TREATMENT OUTCOME; URINALYSIS;

BONE DENSITY; CASE-CONTROL STUDIES; CHILD; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; STEROIDS; TIME FACTORS;

EID: 14644441700     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1790-8     Document Type: Article

References (41)

1. Warady BA, Hébert D, Sullivan EK, Alexander SR, Tejani A (1997) Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 Annual Report of the North American Pediatric Transplant Cooperative Study. Pediatr Nephrol 11:49-64
2. Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). B Johns Hopkins Hosp 50:137
3. Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1997) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541 10.1016/S0140-6736(96)07088-2
5. Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocr Metab 82:265-274 10.1210/jc.82.1.265
6. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 333:1437-43 10.1056/ NEJM199511303332201
7. Tobias JH (1997) How do bisphosphonates prevent fractures? Ann Rheum Dis 56:510-511
8. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283
9. van Persijn van Meerten EL, Kroon HM, Papapoulos SE (1992) Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 184:249-254 1609087
10. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocr Metab 61:952-956
11. Lepore L, Pennesi M, Barbi E, Pozzi R (1991) Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 9(Suppl 6):33-35
12. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A (1998) Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 157:261-262
13. Huaux JP, Lokietek W (1998) Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 8:71-72
14. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G (1997) Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:622-625
15. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363 10.1007/BF00350961
16. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis in children under 3 years of age. J Clin Endocr Metab 85:1846-1850 10.1210/ jc.85.5.1846
17. Rice A, Rivkees S (1999) Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr 134:349-351
18. Attard TM, Dhawan A, Kaufman SS, Collier DS, Langnas AN (1998) Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation. Pediatr Transpl 2:157-159
19. Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE (1994) Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate. Transplantation 57:301-303 1:STN:280:ByuC2czpvFU%3D
20. Rawlinson PS, Green RH, Coggins AM, Boyle IT, Gibson BE (1991) Malignant osteoporosis: Hypercalcaemia after bone marrow transplantation. Arch Dis Child 66:638-639
21. Boudailliez BR, Pautard BJ, Sebert JL, Kremp O, Piussan CX (1990) Leukaemia-associated hypercalcemia in a 10-year-old boy: Effectiveness of aminohydroxypropylidene bisphosphonate. Pediatr Nephrol 4:510-511
22. Young G, Shende A (1998) Use of pamidronate in the management of acute cancer-related hypercalcemia in children. Med Pediatr Oncol 30:117-121
23. Varache N, Audran M, Clochon P, Lortholary A, Bouachour G, Alquier P, Basle MF (1991) Aminohydroxyprophylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcemia in a young patient. Clin Rheumatol 10:328-332
24. McIntyre HD, Cameron DP, Urquhart SM, Davies WE (1989) Immobilization hypercalcemia responding to intravenous pamidronate sodium therapy. Postgrad Med J 65:244-246
25. Sellers E, Sharma A, Rodd C (1998) The use of pamidronate in three children with renal disease. Pediatr Nephrol 12:778-781
26. Jansson S, Tissell LE, Lindstedt G, Lundberg PA (1991) Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 110:480-486
27. Liens D, Delmas PD, Meunier PJ (1994) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343:953-954 10.1016/ S0140-6736(94)90069-8
28. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rignon F, de Sanctis C (2000) Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89:188-193
29. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA (1994) Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 94:385-389
30. Cassinelli HR, Mautalen CA, Heinrich JJ, Miglietta A, Bergada C (1992) Familial idiopathic hyperphosphatasia (FIH): Response to long-term treatment with pamidronate (APD). Bone Miner 19:175-184 10.1016/ 0169-6009(92)90924-3
31. Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969) Diphosphonates in the treatment of myositis ossificans. Lancet 2:845 10.1016/S0140-6736(69)92293-4
32. Rogers JG, Dorst JP, Geho WB (1977) Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr 91:1011-1014
33. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541 10.1016/S0140-6736(96)07088-2
34. Kleerekoper M, Avioli LV (1996) Evaluation and treatment of postmenopausal osteoporosis. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 3rd edn. Lippincott-Raven, Philadelphia, PA, pp 264-271
35. Bell NH, Johnson RH (1997) Bisphosphonates in the treatment of osteoporosis. Endocrine 6:203-206
36. De Groen PC, Lubbe DF, Hirsch LJ et al. (1996) Esophagitis associated with the use of alendronate. New Engl J Med 335:1016-1021 10.1056/ NEJM199610033351403
37. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283
38. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocr Metab 16(6):887-92
39. Shaw NJ, Boivin CM, Crabtree NJ (2000) Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 83(2):143-5 10.1136/adc.83.2.143
40. Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142(4):417-23
41. Noguera A, Ros JB, Pavia C, Alcover E, Valls C, Villaronga M, Gonzalez E (2003) Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocr Metab 16(4):529-36